Published in
Taylor and Francis Group, Leukemia & Lymphoma, 12(61), p. 2821-2830, 2020
DOI: 10.1080/10428194.2020.1786556
Links
Tools
No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group
Journal article published in 2020 by
Thoralf Lange,
Christian Niederwieser 
,
Arthur Gil,
Rainer Krahl,
Ulrich von Grünhagen,
Haifa Kathrin Al-Ali,
Kathleen Jentsch-Ullrich,
Claudia Spohn,
Volker Lakner,
Michael Assmann,
Christian Junghanss,
Michael Cross,
Rüdiger Hehlmann,
Michael Deininger,
Markus Pfirrmann
and other authors.
,
Arthur Gil,
Rainer Krahl,
Ulrich von Grünhagen,
Haifa Kathrin Al-Ali,
Kathleen Jentsch-Ullrich,
Claudia Spohn,
Volker Lakner,
Michael Assmann,
Christian Junghanss,
Michael Cross,
Rüdiger Hehlmann,
Michael Deininger,
Markus Pfirrmann
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 